tbuckley/cabot-search huggingface dataset:
Explicit and implicit attitudes toward lung cancer (LC) relative to breast cancer (BC).
Authors: Joan H. Schiller, Chris J. Bowden, Jennifer Mills, Edward Lang, Holli Dickson, Heidi A Hamann, N. Sriram
Journal: Journal of Clinical Oncology (2013)

8017 Background: Emerging research suggests that LC may be associated with greater levels of stigma, shame and hopelessness compared to other cancers. This study measured explicit, conscious attitudes (EAs) and used the Implicit Association Test (IAT) to assess implicit, unconscious attitudes (IAs) of LC relative to BC. Methods: To assess EAs, participants (Ps), [people with cancer (n=243), caregivers (n=677), healthcare providers (HCPs, n=142), and the general public (n=864)] were asked to rate their agreement, on a six-point scale, with statements about how people with LC and BC “do feel” (descriptive attitudes) or “ought to feel” (normative attitudes) about their disease. IAs were measured with three IATs that used LC or BC images with words representing good/bad; hope/despair; or suitable/shameful. An IAT D score indicated the strength of bias against LC relative to BC: &gt;0.65 = strong bias; 0.35-0.65 = moderate bias; 0.15-0.35 = slight bias; -0.15 -+0.15 = no bias, and &lt; -0.15 indicated bias against BC. Results: EAs and IAs were substantially more negative towards LC. Most Ps provided more negative ratings for LC than BC for both descriptive (70%vs.8%) and normative statements (56% vs. 3%). Ps had strong negative IAs towards LC compared to BC (bad: 74% vs. 10%; despair: 75% vs. 9%; shame: 67% vs. 17%). These trends were consistent across caregivers, patients, HCPs, and the public. EAs and IAs were uncorrelated. Conclusions: Ps had greater explicit and implicit negative bias against LC compared to BC. [Table: see text]
Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV
Authors: Yi Zheng, Gye Won Han, Ruben Abagyan, Beili Wu, Raymond C. Stevens, Vadim Cherezov, Irina Kufareva, Tracy M. Handel
Journal: Immunity (2017)
Efficacy study of metronomic chemotherapy in triple negative metastatic breast cancer.
Authors: Srinivasa Bj, Viveka Belathur Kalegowda, Girish Badarkhe, Sridhar PS, Mansi Khanderia, Tousif T, Bhanu Lalkota, Shruthy Kodad, Mohamed Musheb, Sulav Sapkota, Radheshyam Nayak, Basavalinga S. Ajaikumar
Journal: Journal of Clinical Oncology (2016)

e12569 Background: We evaluated the effects of metronomic chemo (MC) on survival outcomes in refractory MBC population. Methods: 28 subjects with treatment refractory (21) and treatment naive (7) MBC were included in an open label single arm efficacy study of MC. Patients were given a chemotherapy regimen of Tab. Cyclophosphamide 50mg once daily and Tab. Methotrexate 2.5mg twice in a week for 3 months or until the progression of their disease whichever was earlier. Patients were assessed for treatment response using RECIST Criteria (v 1.1) and duration of PFS and OS. Monitoring of S. VEGF and TSP levels were done to correlate the RR. Data were analysed using chi square test for proportions and Kaplan Meir Survival analysis. Results: The mean age of the study population was 51.5 ±14.2 years. The mean duration of MC was 123.89 ±97.6 days. Overall 71.4% had PD and 28.6% had SD. 55.6% with treatment naive MBC had SD compared to 15.8% of treatment refractory MBC (χ2 = 4.7, p = 0.03). There was a significant improvement in OS in those with ECOG of 1 compared to ECOG of 2 (95% CI of Mean 163-294 vs. 38-102 days, Log Rank Mantel Cox = 3.58, p = 0.05) and pathology grade 2 compared to grade 3 (95% CI of Mean 242-400 vs. 92-223 days, Log Rank Mantel Cox = 4.68, p = 0.03) and tumor load less than median (5cms) compared to greater than 5 cms (95% CI of Mean 171-319 vs.54-118days, Log Rank Mantel Cox = 4.45, p = 0.03). There was also a significant improvement in PFS in those with tumor load less than 5 cms compared to > 5cms (95% CI of Mean 126-288 vs. 42-108 days, Breslows Wilcoxon = 3.71, p = 0.05) and in grade 2 compared to grade 3 disease (95% CI of Mean 47-195 vs.31-60 days, Log Rank Mantel Cox = 5.58, p = 0.02). There was no correlation of serum VEGF levels before and after chemotherapy (95% CI of Mean 133.3±70.6vs 145±87, p = .59). There is no significant decrease in TSP levels (95% CI of Mean 86±34 vs. 67±42, p = .24). Conclusions: The results suggest stable response in one third of study patients, PFS and OS rates following MC. PS and tumor load are important predictors in this category of population. There is no significant correlation of serum VEGF and TSP levels before and after chemotherapy. Also, there was no significant correlation of biomarker levels in responding and non-responding patients.
Further Observations on Inhibition of Lymphoid Tumor Development by Shielding and Partialbody Irradiation of Mice&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Henry S. Kaplan, Mary B. Brown
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Further Observations on Inhibition of Lymphoid Tumor Development by Shielding and Partialbody Irradiation of Mice Get access Henry S. Kaplan, Henry S. Kaplan Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary B. Brown Mary B. Brown Department of Radiology, Stanford University School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 2, October 1951, Pages 427–436, https://doi.org/10.1093/jnci/12.2.427 Published: 01 October 1951 Article history Received: 04 June 1951 Published: 01 October 1951
Abstract 97: Ablation of Calpain-Targeted Site in Cardiac Myosin Binding Protein C Is Cardioprotective
Authors: Sakthivel Sadayappan, Xiang Ji, David Barefield, Jason Sarkey, Suresh Govindan, Younss Aitmou, Guangshuo Zhu, Eiki Takimoto, Pradeep K Luther, Dobromir Dobrev, David A Kass, Pieter P de Tombe
Journal: Circulation Research (2012)

Rationale: Cardiac myosin binding protein-C (cMyBP-C) phosphorylation is essential for normal heart function. We recently demonstrated a direct correlation between cMyBP-C dephosphorylation and its degradation during ischemia-reperfusion (I-R) injury. Strikingly, cMyBP-C phosphorylation protects the heart from I-R injury. However, the mechanism of cMyBP-C-mediated cardioprotection is unknown. Objective: To determine if preventing cMyBP-C proteolysis and cleavage confers cardioprotection during I-R injury. Methods and Results: cMyBP-C is a substrate for calpains and dephosphorylation makes cMyBP-C more susceptible to proteolysis. In patients with heart failure, such proteolysis leads to the cleavage and release of the predominant N'-fragment (40 kDa) in association with increased calpain activity. MS/MS analysis identified a cardiac-specific phosphorylation motif responsible for the release of the 40 kDa fragment, 272-TSLAGAGRR-280, which we term the calpain-targeted site (CTS). Next, we utilized cardiac-specific transgenic mice expressing cMyBP-C[[Unable to Display Character: △]]CTS in which CTS motif was ablated and bred into cMyBP-C null (t/t) mice. We hypothesized that ablation of the CTS motif would confer resistance to calpain-mediated proteolysis and thus protect the heart from I-R injury. An animal that transgenically expressed the normal cardiac isoform, cMyBP-CWT, served as a control. Histological, electron microscopic and immunofluorescence analyses confirm that cMyBP-C[[Unable to Display Character: &amp;#8710;]]CTS incorporates normally into the cardiac sarcomere and results in complete rescue of the cMyBP-Ct/t phenotype, compared control groups. Moreover, echocardiography and in vivo hemodynamic studies revealed that cMyBP-C[[Unable to Display Character: &amp;#8710;]]CTS:t/t mice have normal cardiac function, similar to control mice. Altogether, these data suggest that cMyBP-C[[Unable to Display Character: &amp;#8710;]]CTS is benign. Compared to cMyBP-CWT, cMyBP-C[[Unable to Display Character: &amp;#8710;]]CTS protein is protected from calpain-mediated degradation. Finally, we determined that ablation of the CTS reduced infarct size and preserved cMyBP-C stability and cardiac function during I-R injury. Conclusion: Our data suggest that preserving cMyBP-C stability by thwarting calpain-mediated proteolysis protects cardiac structure and function from I-R injury, as a supportive therapy.
Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.
Authors: Irene Wapnir, Allison W. Kurian, Daphne Lichtensztajn, Christina A Clarke, Scarlett Lin Gomez
Journal: Journal of Clinical Oncology (2016)

1052 Background: The benefits of NAC for breast cancer are multifaceted, providing insight into chemosensitivity, facilitating breast conservation, and providing prognostic information. However, little is known about NAC use across patient demographic factors and health care settings, or trends in surgical procedures after NAC. Methods: Women diagnosed with Stage I-III breast cancer in California, 1998-2012 were identified from the California Cancer Registry. Use of NAC, adjuvant chemotherapy (aCTx) and type of surgery (breast conserving surgery (BCS), bilateral mastectomy (BLM), unilateral mastectomy (ULM)) were examined as a function of clinical, pathological, and sociodemographic and hospital factors. Results: Among 236,797 patients, 34.9% received aCTx, 5.2% NAC and 59.9% no chemotherapy (NoCTx). NAC use nearly tripled over this time period (3.5%-10.8%). Among chemotherapy recipients, NAC use was higher with stage (Stage I, 3.7%; Stage III, 29.1%), was highest for women age < 40 (20.0%) and fell to 13.8% for 40-49 years, 11.8% for 50- 64 years and 10.3% for age ≥ 65. On multivariable analysis, predictors of NAC use included higher stage (III) and grade (3), younger age ( < 40 years), Hispanic (H) ethnicity [versus non-H White, odds ratio (OR) 1.10, 95% confidence interval (CI) 1.05-1.16], and care at a National Cancer Institute (NCI)-designated cancer center (OR 1.70, CI 1.58-1.82). 54.1% of NAC recipients had ULM; 31.6% had BCS and 14.3% BLM. By comparison, lower rates of BLM, 7.4% and 4.3% were recorded among aCTx and NoCTx recipients, respectively. Both BCS and BLM use after NAC increased over time, except for BCS among women < 50 years. The only independent predictor of BCS use after NAC was care at a cancer center (OR 1.70, CI 1.58-1.82). For BLM after NAC, age < 40 (vs. 50-64, OR 2.59, CI 2.21-3.03) or high socioeconomic status neighborhood (vs. low, OR 2.10, CI 1.67-2.64) were the only predictive factors. Conclusions: Although NAC use nearly tripled over time, it remains low, albeit more prevalent in cancer centers. In parallel, BLM use quadrupled after NAC, and was less common after aCTx or NoCTx. High BLM use after NAC warrants investigation, with regard to treatment intent and quality of care.
Prise en charge initiale des cancers épidermodes de l'isophage: qualité du compte rendu d'endoscopie
Authors: V Granger, E Assenat, F Blanc, P Blanc, P Poudouroux, M Ychou, P Senesse
Journal: Endoscopy (2005)

Des recommandations pour la pratique sont régulièrement mises à jour par les sociétés savantes, mais peu de travaux étudient leur application. L'objectif principal de ce travail était d'évaluer, lors de la prise en charge initiale des cancers épidermodes de l'csophage, les pratiques endoscopiques par rapport aux recommandations actuellement publiées.
Elastographie guidée par echoendoscopie: premiers pas vers la biopsie virtuelle? résultats d'une étude préliminaire chez 26 patients
Authors: M Giovannini, E Bories, CH Pesenti, G Monges, V Moutardier, JR Delpero
Journal: Endoscopy (2005)

Rationnel L'élastographie est une nouvelle technologie dans laquelle les modifications de contrainte des tissus sont employées pour détecter des tumeurs. Une tumeur cancéreuse est normalement 5–10 fois plus «rigide» que le tissu normal. Quand une compression mécanique est appliquée, la tumeur se déforme moins que le tissu environnant c. -à-d. La contrainte dans la tumeur est moindre que dans le tissu environnant. Cette propriété produit des images remarquablement claires. Le but de cette étude a été d'appliquer cette nouvelle technologie à l'échoendoscopie pour le diagnostic de malignité des masses du pancréas et des adénopathies.
Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis
Authors: Patrick J. Stiff, Hongli Li, James R. Cook, Louis S. Constine, Stephen Couban, Douglas A. Stewart, Thomas C. Shea, Pierluigi Porcu, Jane N. Winter, Brad S Kahl, Sonali M. Smith, Deborah Marcellus, Kevin Barton, Glenn M. Mills, Michael LeBlanc, Lisa Rimsza, Stephen J. Forman, John P. Leonard, Richard I. Fisher, Jonathan Friedberg
Journal: Blood (2016)
Incidence des hypoxémies au cours des endoscopies digestives réalisées sous anesthésie générale
Authors: P Abback, JJ Raynaud, H Hermann, S Racine, JL Fournier, B Bejou, C Bon, G Airinei, R Benamouzig, C Baillard
Journal: Endoscopy (2009)

Introduction: L'hypoxémie est la principale complication pulmonaire lors de l'endoscopie digestive avec anesthésie générale mais elle reste encore peu étudiée. Elle est favorisée par le geste endoscopique (gêne mécanique diaphragmatique pour la coloscopie, obstruction pharyngée pour la gastroscopie) et la sédation. La majorité des endoscopies sont réalisées en ventilation spontanée. L'objectif principal de cette étude était d'évaluer prospectivement l'incidence des hypoxémies observées au cours des endoscopies digestives réalisées sous anesthésie générale et d'identifier des facteurs de risques de leurs survenues.
Cryopreservation and Thawing of Hematopoietic Stem Cells CD34 Induced Apoptosis through Caspases Pathway Activation
Authors: Hicham Bouhlal, Veronique Harrivel, Christèle Ossart, Marie Noelle Lacassagne, Aline Reignier, Jean-Pierre Marolleau
Journal: Blood (2014)
Effect of patient directed input on genetic testing in the surgical setting.
Authors: Linda Ann Smith, Kathryn A Wagner, Eric B Whitacre, Eric Allen Brown, Angela Soto-Hamlin, Kay M Shawchuck
Journal: Journal of Clinical Oncology (2016)

e13117 Background: Genetic risk analysis hinges on patient provided data. Family history facts when reported by a patient at intake is notably hasty and incomplete. To remedy this weakness an iPad based intake system was designed and supported by Invitae. This system allowed single entry for multiple risk analyses for breast and colon cancer, MRI qualification, and genetic testing. Methods: Six breast surgeons, members of the American Society of Breast Surgeons introduced the iPad into their clinical practice. Software was customized for iPad technology. During the 3 month trial period each patient was asked to use the iPad to enter data appropriate for risk assessment. The data was then linked to the American Society of Breast Surgeons site, processed, and a patient friendly print out was generated Results: 1500 patients were evaluated by 6 surgeons over a 3 month period. This was compared to the general population of ASBrS surgeons numbering 499 who as a group saw 20969 patients and entered 5685 risk assessments. The patients of the pilot surgeons (100% risk assessment) enjoyed a 13.7% testing rates for genetic abnormality and a positivity rate of 13.1. The patients of the non-participating surgeons, 27.1% underwent risk analysis, 1% had genetic testing with a 16.5% positive rate. Conclusions: The act of measuring family history is important and time consuming. The iPad was found to be usable by greater than 90% of the patients. The surgeons reported it was generally time neutral but greatly increased accuracy. It correctly identified high risk patients for MRI and genetic testing. It dramatically increased the number of patients being tested for genetic abnormalities over other breast surgeons. No increase in over-testing was identified. This technology should be considered for widespread utilization with exceptionally high patient acceptance and extraordinarily large changes in patient management for very little cost of risk. Had Genetic Testing Percentage of pts seen who had Genetic Testing Tested Positive Of those tested, percent positive With Cancer Outside of Pilot 112 3.5% 10 8.9% Pilot 113 23.4% 7 6.2% Without Cancer Outside of Pilot 106 0.6% 26 24.5% Pilot 93 9.1% 20 21.5%
Traitement de la lithiase biliaire en un temps par cholécystectomie laparoscopique et sphinctérotomie endoscopique per opératoire chez 204 malades
Authors: T Barrioz, M Happi Nono, JP Faure, JC Letard, JP Richer, M Carretier, M Beauchant
Journal: Endoscopy (2005)

Le traitement de la lithiase de la voie biliaire (LVBP) découverte lors d'une cholangiographie per opératoire, reste un sujet très débattu, mais la tendance actuelle est de réaliser un traitement en un temps. Le but de ce travail prospectif est d'évaluer la faisabilité, l'efficacité et les complications à court et long terme de la sphinctérotomie endoscopique per opératoire réalisée chez les malades avec découverte ou forte suspicion de LVBP lors d'une cholécystectomie laparoscopique.
C/EBPβ Is a Critical Regulator of CML Stem Cell Differentiation and Exhaustion Induced By Interferon-α
Authors: Asumi Yokota, Hideyo Hirai, Yoshihiro Hayashi, Ryuichi Sato, Hiroko Adachi, Fumiko Sato, Atsushi Sato, Akihiro Tamura, Masaki Iwasa, Aya Fujishiro, Tsukimi Shoji, Takahiro Kashiwagi, Naoka Kamio, Yusuke Torikoshi, Yasuo Miura, Masakazu Nakano, Kei Tashiro, Taira Maekawa
Journal: Blood (2016)
A new marker for colorectal cancer
Authors: RM McLoughlin, E Shiel, SS Sebastian, B Ryan, HJ O'Connor, C O'Morain
Journal: Endoscopy (2005)

Introduction: Pyruvate kinase is a key enzyme in the glycolytic pathway and determines the relative amount of glucose that is channelled into synthetic processes or used for glycolytic ATP production. One of its isoenzymes, tumour M2-PK channels phosphometabolites towards synthetic processes.
Rare Endobronchial Inflammatory Myofibroblastic Tumor in Pediatric Patient Detected on PET/CT Imaging
Authors: Pelin Ozcan Kara, Zehra Pinar Koc, Elvan Caglar Citak, Ali Nayci, Gokhan Berktug Bahadir, Taylan Kara
Journal: Clinical Nuclear Medicine (2017)

Inflammatory myofibroblastic tumor (IMT) can be seen in all age groups, although it is more common in children and adolescents. We report the FDG PET/CT findings in an 8-year-old boy with endobronchial IMT. Endobronchial IMT is more commonly seen in young adults.
Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
Authors: Geraldine Helen O'Sullivan Coyne, Shivaani Kummar, Robert S. Meehan, Howard Streicher, Naoko Takebe, Elad Sharon, Barbara A. Conley, Lyndsay Harris, Jerry M. Collins, Nancy Moore, Lamin Juwara, Larry Rubinstein, Mary Flanagan Quinn, Yves Pommier, Mark Cushman, James H. Doroshow, Alice P. Chen
Journal: Journal of Clinical Oncology (2017)

2558 Background: Indenoisoquinolines (ID) are non-camptothecin inhibitors of topoisomerase (TOP1) identified following a COMPARE analysis of the National Cancer Institute’s (NCI) in vitro anticancer drug discovery screen. IDs have improved characteristics over camptothecin top1 inhibitors, with better chemical stability (lacking the labile hydroxylactone E-ring) producing stable DNA breaks that are resistant to reversal of the trapped DNA-TOP1 cleavage complex and at different DNA sequence sites to camptothecins (Kohlhagen et al. Mol Pharmacol. 2005). IDs have shown more activity against camptothecin-resistant cell lines and mouse models, as well as in cells overexpressing the ATP-binding cassette (ABC) transporters, and multidrug resistance (MDR-1/ABCB1) genes. A parallel first-in-human Phase I study conducted at the NCI of LMP400 in patients with refractory solid tumors and lymphomas showed this molecule to be well tolerated (Kummar et al, Cancer Chemother Pharmacol. 2016). A trial of LMP776 (NSC725776), has completed accrual. Primary Objectives: define the maximum tolerated dose (MTD) of LMP776 and the dose-limiting toxicities (DLTs). Methods: Phase I trial using Design 4 of the Simon accelerated titration designs (Simon et al. JNCI, 1997), with doses escalated based on toxicity during cycle 1. LMP776 was administered via central line QD over 1 hour on days 1–5 q 28-days. Response is defined by RECIST 1.1 on CT. Results: 32 of 34 patients (pts) were evaluable for toxicity and response. Enrollment was expanded at dose level (DL) 2 to 6 pts due to a hypocalcemia DLT, with subsequent enrollment on a 3+3 design. MTD was established at DL7 (12mg/m 2 , DLT myelosuppression). Common Grade 3/4 adverse events by CTCAE v.4 included anemia (5 pts, 15%), thrombocytopenia (5), lymphopenia (5) and neutropenia (3 pts, 9%). 12 (37%) pts experienced stable disease (SD), with a median of 4 cycles of treatment (range 2-9). 10 (30%) pts with SD remained on study for ≥4 months, with 4 pts on study ≥6 months. Conclusions: LMP776 is overall well tolerated. Explorative correlatives and additional trials are being considered. Clinical trial information: NCT01051635.
The impact of the total size of lesions in multifocal/multicentric breast cancer on survival.
Authors: Yusuf Karakas, Omer Dizdar, Serkan Akin, Ozturk Ates, Mehmet Ali Nahit Sendur, Sercan Aksoy, Mutlu Hayran, Ibrahim Halil Gullu, Yavuz Yasin Ozisik, Kadri Altundag
Journal: Journal of Clinical Oncology (2016)

e12030 Background: Multifocal/multicentric(MF/MC) may be observed in 20% of patients with breast cancer.According to AJCCstaging system, the T stage of a tumor is determined based on the size of the largest lesion in the breast; however, some data suggest that considering the total size of the lesions is more valuable.We investigated and compared the prognostic value of determining the T stage according to the total size of lesions and according to the size of the largest lesion alone in patients with MF/MC breast cancer. Methods: The pathology reports of patients with breast cancer who were monitored at Hacettepe University 2003 and 2014 were reviewed. The T stage of MF/MC tumors was determined according to the largest lesion size (Tfirst ) and the sum of the longest diameters of the lesions (Tlast ). The impact of both T stages on DFS and OS was evaluated. Results: MF/MC tumors were diagnosed in 323 of 3890 patients with breast cancer (8.3%). When the T stage was determined by summing the sizes of the lesions, the T stage of 67 (20.7%) and 63 (19.5%) patients advanced from T1 to T2 and T2 to T3, respectively. Thus, the T stage in a total of 130 patients with MF/MC (40.2%) increased (32 patients from AJCC stage I to II and 13 patients from stage II to III). AJCC stage changed in a total of 45 patients (14%). In patients with unifocal and MF/MC tumors, the 10-year OS was 75% and 74%, respectively (p = 0.965) and the 10-year DFS was 66% and 61%,respectively (p = 0.817). It was observed that the DFS curves of the patients with MF/MC tumors whose T stage advanced from phase I to II according to Tfirst and Tlast (n = 32) overlapped with the survival curves of the patients with unifocal tumors whose was stage I, particularly in the first 3 years. The 3-year DFS was found to be 97.2% in patients with unifocal tumors of stage 1, 91.6% in patients with stage 2, and 100% in patients whose multifocal stage advanced from I to II according to Tlast . The independent predictors of DFS were found to be Tfirst , hormone receptor positivity, and lymph node involvement. There was no significant relationship between Tlast and DFS. Conclusions: It was observed that the T stage obtained by summing lesion sizes in patients with MF/MC breast cancer is not superior to the classic staging in terms of prognosis.